{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:02:11Z","timestamp":1790352131865,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T00:00:00Z","timestamp":1662768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T00:00:00Z","timestamp":1662768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Myelodysplastic syndromes (MDS) are clonal hematopoietic diseases of the elderly characterized by chronic cytopenias, ineffective and dysplastic haematopoiesis, recurrent genetic abnormalities and increased risk of progression to acute myeloid leukemia. A challenge of routine laboratory Complete Blood Counts (CBC) is to correctly identify MDS patients while simultaneously avoiding excess smear reviews. To optimize smear review, the latest generations of hematology analyzers provide new cell population data (CPD) parameters with an increased ability to screen MDS, among which the previously described MDS-CBC Score, based on Absolute Neutrophil Count (ANC), structural neutrophil dispersion (Ne-WX) and mean corpuscular volume (MCV). Ne-WX is increased in the presence of hypogranulated\/degranulated neutrophils, a hallmark of dysplasia in the context of MDS or chronic myelomonocytic leukemia. Ne-WX and MCV are CPD derived from leukocytes and red blood cells, therefore the MDS-CBC score does not include any platelet-derived CPD. We asked whether this score could be improved by adding the immature platelet fraction (IPF), a CPD used as a surrogate marker of dysplastic thrombopoiesis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Here, we studied a cohort of more than 500 individuals with cytopenias, including 168 MDS patients. In a first step, we used Breiman\u2019s random forests algorithm, a machine-learning approach, to identify the most relevant parameters for MDS prediction. We then designed Classification And Regression Trees (CART) to evaluate, using resampling, the effect of model tuning parameters on performance and choose the \u201coptimal\u201d model across these parameters.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Using random forests algorithm, we identified Ne-WX and IPF as the strongest discriminatory predictors, explaining 37 and 33% of diagnoses respectively. To obtain \u201csimplified\u201d trees, which could be easily implemented into laboratory middlewares, we designed CART combining MDS-CBC score and IPF. Optimal results were obtained using a MDS-CBC score threshold equal to 0.23, and an IPF threshold equal to 3%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We propose an extended MDS-CBC score, including CPD from the three myeloid lineages, to improve MDS diagnosis on routine laboratory CBCs and optimize smear reviews.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-10059-8","type":"journal-article","created":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T21:02:22Z","timestamp":1662843742000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Machine learning-based improvement of MDS-CBC score brings platelets into the limelight to optimize smear review in the hematology laboratory"],"prefix":"10.1186","volume":"22","author":[{"given":"Jaja","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Lemaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Mathis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Ronez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Clauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katayoun","family":"Jondeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Ad\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0271-3357","authenticated-orcid":false,"given":"Val\u00e9rie","family":"Bardet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,10]]},"reference":[{"key":"10059_CR1","first-page":"98","volume-title":"WHO classification of tumors of Haematopoietic and lymphoid tissues. Revised","author":"SH Swerdlow","year":"2017","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumors of haematopoeitic and lymphoid tissues. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumors of Haematopoietic and lymphoid tissues. Revised. 4th ed. Lyon, France: IARC; 2017. p. 98\u2013106.","edition":"4"},{"issue":"6","key":"10059_CR2","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079\u201388.","journal-title":"Blood."},{"issue":"12","key":"10059_CR3","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454\u201365.","journal-title":"Blood."},{"key":"10059_CR4","first-page":"98","volume-title":"WHO classification of tumors of Haematopoietic and lymphoid tissues. Revised","author":"RP Hasserjian","year":"2017","unstructured":"Hasserjian RP, Orazi A, Brunning RD, Germing U, Le Beau MM, Porwit A, et al. Myelodysplastic syndromes: overview. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumors of Haematopoietic and lymphoid tissues. Revised. 4th ed. Lyon, France: IARC; 2017. p. 98\u2013106.","edition":"4"},{"issue":"26","key":"10059_CR5","doi-asserted-by":"publisher","first-page":"7121","DOI":"10.1182\/blood-2011-02-337964","volume":"117","author":"CR Cogle","year":"2011","unstructured":"Cogle CR, Craig BM, Rollison DE, List AF. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood. 2011;117(26):7121\u20135.","journal-title":"Blood."},{"issue":"2","key":"10059_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1532\/LH96.05019","volume":"11","author":"PW Barnes","year":"2005","unstructured":"Barnes PW, McFadden SL, Machin SJ, Simson E, review Icgfh. The international consensus group for hematology review: suggested criteria for action following automated CBC and WBC differential analysis. Lab Hematol. 2005;11(2):83\u201390.","journal-title":"Lab Hematol"},{"issue":"8","key":"10059_CR7","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1097\/00007611-198708000-00009","volume":"80","author":"ES Rappaport","year":"1987","unstructured":"Rappaport ES, Helbert B, Ladd DJ, Trowbridge AA. Myelodysplastic syndrome: identification in the routine hematology laboratory. South Med J. 1987;80(8):969\u201374.","journal-title":"South Med J"},{"issue":"5","key":"10059_CR8","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/bjh.15626","volume":"183","author":"R Boutault","year":"2018","unstructured":"Boutault R, Peterlin P, Boubaya M, Sockel K, Chevallier P, Garnier A, et al. A novel complete blood count-based score to screen for myelodysplastic syndrome in cytopenic patients. Br J Haematol. 2018;183(5):736\u201346.","journal-title":"Br J Haematol"},{"issue":"3","key":"10059_CR9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1080\/00365513.2018.1423702","volume":"78","author":"F Schillinger","year":"2018","unstructured":"Schillinger F, Sourdeau E, Boubaya M, Baseggio L, Clauser S, Cornet E, et al. A new approach for diagnosing chronic myelomonocytic leukemia using structural parameters of Sysmex XN(TM) analyzers in routine laboratory practice. Scand J Clin Lab Invest. 2018;78(3):159\u201364.","journal-title":"Scand J Clin Lab Invest"},{"issue":"3","key":"10059_CR10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/cyto.b.21947","volume":"100","author":"A Shestakova","year":"2021","unstructured":"Shestakova A, Nael A, Nora V, Rezk S, Zhao X. Automated leukocyte parameters are useful in the assessment of myelodysplastic syndromes. Cytometry B Clin Cytom. 2021;100(3):299\u2013311.","journal-title":"Cytometry B Clin Cytom"},{"key":"10059_CR11","doi-asserted-by":"publisher","unstructured":"Ravalet N, Foucault A, Picou F, Gombert M, Renoult E, Lejeune J, et al. Automated early detection of myelodysplastic syndrome within the general population using the research parameters of Beckman-coulter DxH 800 hematology analyzer. Cancers (Basel). 2021;13(3):389. https:\/\/doi.org\/10.3390\/cancers13030389.","DOI":"10.3390\/cancers13030389"},{"key":"10059_CR12","doi-asserted-by":"publisher","unstructured":"Hwang SM, Nam Y. Complete blood count and cell population data parameters from the Abbott Alinity hq analyzer are useful in differentiating myelodysplastic syndromes from other forms of cytopenia. Int J Lab Hematol.\u00a02022;44(3):468\u201376. https:\/\/doi.org\/10.1111\/ijlh.13777. Epub 2021 Dec 7.","DOI":"10.1111\/ijlh.13777"},{"issue":"8","key":"10059_CR13","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1515\/cclm-2014-0165","volume":"52","author":"JJ Hoffmann","year":"2014","unstructured":"Hoffmann JJ. Reticulated platelets: analytical aspects and clinical utility. Clin Chem Lab Med. 2014;52(8):1107\u201317.","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"10059_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1532\/LH96.09003","volume":"15","author":"K Saigo","year":"2009","unstructured":"Saigo K, Takenokuchi M, Imai J, Numata K, Isono S, Zenibayashi M, et al. Usefulness of immature platelet fraction for the clinical evaluation of myelodysplastic syndromes. Lab Hematol. 2009;15(2):13\u20136.","journal-title":"Lab Hematol"},{"issue":"1","key":"10059_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1600-0609.2008.01156.x","volume":"82","author":"N Sugimori","year":"2009","unstructured":"Sugimori N, Kondo Y, Shibayama M, Omote M, Takami A, Sugimori C, et al. Aberrant increase in the immature platelet fraction in patients with myelodysplastic syndrome: a marker of karyotypic abnormalities associated with poor prognosis. Eur J Haematol. 2009;82(1):54\u201360.","journal-title":"Eur J Haematol"},{"issue":"10","key":"10059_CR16","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1179\/1607845415Y.0000000021","volume":"20","author":"K Miyazaki","year":"2015","unstructured":"Miyazaki K, Koike Y, Kunishima S, Ishii R, Danbara M, Horie R, et al. Immature platelet fraction measurement is influenced by platelet size and is a useful parameter for discrimination of macrothrombocytopenia. Hematology. 2015;20(10):587\u201392.","journal-title":"Hematology."},{"key":"10059_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.thromres.2020.06.048","volume":"195","author":"N Benlachgar","year":"2020","unstructured":"Benlachgar N, Doghmi K, Masrar A, Mahtat EM, Harmouche H, Tazi MZ. Immature platelets: a review of the available evidence. Thromb Res. 2020;195:43\u201350.","journal-title":"Thromb Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10059-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10059-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10059-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T21:02:46Z","timestamp":1662843766000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10059-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,10]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10059"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10059-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,10]]},"assertion":[{"value":"11 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All investigations performed in this study were in accordance with the Helsinki Declaration, and were approved by the Institutional Review Board Nantes IV (MODIFY study: 2018-A00691\u201354). Informed consent was obtained from all patients included in the MODIFY study and\/or in the Groupe Francophone des My\u00e9lodysplasies (GFM) French National registry of MDS.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"972"}}